Travere Therapeutics (TVTX) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Travere Therapeutics (TVTX) stock.

Latest Upgrades and Downgrades for Travere Therapeutics Stock

Date	Firm	Analyst	Action	Rating Change	Price Target
—	JP Morgan	Anupam Rama	PT Cut	Overweight	$90→$86
—	Leerink Partners	Joseph Schwartz	PT Cut	Outperform	$78→$67
—	Canaccord Genuity	Edward Nash	PT Raise	Buy	$70→$72
—	Guggenheim	Vamil Divan	PT Cut	Buy	$89→$78
—	Guggenheim	Vamil Divan	PT Raise	Buy	$75→$89
—	Wedbush	Laura Chico	Maintained	Outperform	$76
—	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$67
—	Evercore ISI Group	Liisa Bayko	PT Raise	Outperform	$68→$78
—	Canaccord Genuity	Edward Nash	PT Raise	Buy	$62→$70
—	Wedbush	Laura Chico	PT Raise	Outperform	$61→$75
—	TD Cowen	Tyler Van Buren	PT Raise	Buy	$60→$75
—	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$70→$85
—	Evercore ISI Group	Liisa Bayko	PT Raise	Outperform	$60→$68
—	Guggenheim	Vamil Divan	PT Raise	Buy	$65→$75
—	Canaccord Genuity	Edward Nash	PT Raise	Buy	$56→$62
—	Guggenheim	Vamil Divan	PT Raise	Buy	$56→$65
—	Wedbush	Laura Chico	PT Raise	Outperform	$55→$61
—	Evercore ISI Group	Liisa Bayko	PT Raise	Outperform	$52→$60
—	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$62→$70
—	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$50→$65

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67

Leerink Partners analyst Joseph Schwartz maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and lowers the price target from $78 to $67.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $72

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $70 to $72.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78

Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and lowers the price target from $89 to $78.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $75 to $89.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $76 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $67 price target.

Benzinga Newsdesk

Travere Therapeutics Inc

Travere Therapeutics (TVTX) Stock Price Target 2026

Latest Upgrades and Downgrades for Travere Therapeutics Stock

Travere Therapeutics (TVTX) Stock Price Target 2026

Latest Upgrades and Downgrades for Travere Therapeutics Stock

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67

PRO
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $72

PRO
Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78

PRO
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

PRO
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67

PRO
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $72

PRO
Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78

PRO
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

PRO
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

Travere Therapeutics Inc

Travere Therapeutics (TVTX) Stock Price Target 2026

Latest Upgrades and Downgrades for Travere Therapeutics Stock

Travere Therapeutics (TVTX) Stock Price Target 2026

Latest Upgrades and Downgrades for Travere Therapeutics Stock

Analyst Ratings News

PROLeerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67

PROCanaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $72

PROGuggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78

PROGuggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

PROWedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

PROHC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PROLeerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67

PROCanaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $72

PROGuggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78

PROGuggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

PROWedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

PROHC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

PRO
Leerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67

PRO
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $72

PRO
Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78

PRO
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

PRO
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

PRO
Leerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67

PRO
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $72

PRO
Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78

PRO
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

PRO
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target